The inflammatory response directly after trauma is related to the development of infectious complications during hospital admission ([@R1]--[@R4]). Injury causes tissue damage, and it is assumed that the resulting production of cytokines and damage-associated molecular patterns are the fuel in this inflammatory process. However, these mediators are numerous, diverse, and many cannot be timely and adequately identified nor quantified. Neutrophils, as part of the final common pathway in inflammation, are responsive to these mediators. These cells integrate the signals into a specific cellular response ([@R5], [@R6]). This cellular response can then be used as a "simple" biomarker of complex systemic inflammation ([@R4]). Changes in neutrophil phenotype can be seen within minutes after trauma, and these changes are dynamic over time ([@R3]). Differential expression of neutrophil markers is thought to be a putative measurement of the amplitude of the tissue damage and the following immunologic response after trauma ([@R5]--[@R9]). Furthermore, the literature suggests that neutrophil marker expression immediately after trauma has predictive value for infectious complications later on ([@R10], [@R11]). Early detection of patients at risk for infectious complications allows for immuno-based treatment decisions after trauma such as timing and intensity of surgery ([@R4], [@R12]).

Until recently, analysis of neutrophil marker expression by flow cytometry was time consuming, labor intensive, and subject to many manual steps that cause data variability. These technical difficulties hamper the clinical application of neutrophil analyses early after trauma.

However, with the introduction of an easy to use, fully automated flow cytometer, it is now possible to obtain flow cytometry results point-of-care within 20 minutes ([@R13], [@R14]). This method enables the phenotyping of neutrophils and other immune cells that can be performed quickly as a point-of-care test by any healthcare worker. Standardization and shortening of ex-vivo processing steps provide highly reproducible data ([@R13]). Furthermore, such an approach minimizes alterations of neutrophil marker expression due to ex vivo manipulation. Therefore, this method might give better and new insights into the cell's true biological features.

The study aim was to test whether 24/7 point-of-care analysis of neutrophil marker expression by automated flow cytometry can be achieved after trauma. Second, the hypothesis was tested whether shifts in neutrophil phenotype were associated with the injury severity score and infectious complications later on.

MATERIALS AND METHODS
=====================

Study Design
------------

All trauma patients presented in the trauma bay of the emergency department of the University Medical Center Utrecht were prospectively screened for inclusion from November 26, 2018, to February 12, 2019. Exclusion criteria were as follows: 1) age less than 18 years, 2) transfer from another hospital, and 3) no diagnostic blood sampling needed. If a patient was eligible for inclusion, blood was drawn and analyzed. Informed consent was obtained in the period thereafter, details are provided in the **Supplemental Methods** (Supplemental Digital Content 1, <http://links.lww.com/CCX/A224>). The medical ethical committee of the University Medical Center Utrecht approved this study under study protocol no. 17/899/D. All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments. The study was approved and registered online by the Central Committee on Research Involving Human Subjects in The Netherlands under protocol no. NL64100.041.17.

Study Procedure
---------------

If blood was drawn from the patient for standard-of-care diagnostic workup during resuscitation, one extra 4-mL Vacutainer sodium heparin blood tube (Becton Dickinson, Oakville, ON) was drawn specifically for this study. Thereafter, a member of the trauma team placed the blood tube in the automated AQUIOS CL "Load & Go" flow cytometer (Beckman Coulter, Miami, FL) that was located in the corner of the trauma room. Data generated by the machine were stored on the computer with a study identification code, generated by the machine.

Flow Cytometry Analysis by the Automated AQUIOS CL "Load & Go" Flow Cytometer
-----------------------------------------------------------------------------

The AQUIOS CL combines robotic automated sample preparation with automated analysis of cells using flow cytometry ([@R13]). The details of these procedures are provided in the Supplemental Methods (Supplemental Digital Content 1, <http://links.lww.com/CCX/A224>).

For this research purpose, two customized antibody mixes were made, and both panels were tested in the presence and absence of the bacterial/mitochondrial derived stimulus formyl-methionyl-leucyl-phenylalanine (fMLF) (Sigma Aldrich, St. Louis, MO) with an end concentration of 10^--6^ M. Details of antibody mixes are provided in the Supplemental Methods (Supplemental Digital Content 1, <http://links.lww.com/CCX/A224>).

Analysis of Flow Cytometry Data
-------------------------------

Multidimensional FLow cytometric Orthogonal Orientation for Diagnosis (FLOOD) analysis was used to do explorative data analysis ([@R15]). For definitive analysis, the.lmd data files were exported from the AQUIOS CL and imported into FlowJo analysis software (Tree Star Inc., Ashland, OR). Neutrophils were gated based on forward scatter and side scatter. Neutrophils in the polymorphonuclear leukocytes gate were identified based on CD16 positivity, thereby excluding eosinophils. Then, neutrophil markers were analyzed in the absence (resting) and presence (activated) of fMLF.

Neutrophil phenotypes were identified by the expression of CD16 and CD62L as described in detail before ([@R16]). The markers CD16 and CD62L were present in panel 1 and panel 2 allowing for bench marking between both panels. **Online supplement figure 1** (Supplemental Digital Content 2, <http://links.lww.com/CCX/A225>) shows the gating strategy to identify neutrophil phenotypes. The average percentage of neutrophil phenotypes as determined by both panels was used. Gating strategy was checked for every individual patient by two independent researchers.

Clinical Data
-------------

Baseline characteristics and clinical outcomes of the included patients were recorded. Data were collected by the treating clinician and anonymously analyzed. Details of reported infectious complications are provided in the Supplemental Methods (Supplemental Digital Content 1, <http://links.lww.com/CCX/A224>).

Statistical Analysis
--------------------

Data were analyzed with IBM SPSS version 23 (IBM Corporation, North Castle, NY) and GraphPad Prism Version 7 (GraphPad Software Inc., San Diego, CA). Statistical significance was defined as a *p* value of less than 0.05. Data are presented as median with interquartile range. Clinical outcomes and demographics were compared between polytrauma patients developing infectious complications and those who did not. To test whether the %CD16^dim^/CD62L^bright^ neutrophils could be univariate predictors for infectious complications in trauma patients, receiver operating characteristic curves were calculated.

RESULTS
=======

Study Overview
--------------

In the period from November 26, 2018, to February 2, 2019, a total of 233 patients were presented in the trauma bay of our emergency department that led to the activation of the whole trauma team. The following patients were excluded from our study (**Fig. [1](#F1){ref-type="fig"}**): patients less than 18 years (*n* = 40), patients who did not need standard diagnostic blood drawing (*n* = 15), and patients who were transferred from another hospital (*n* = 14). This resulted in a total of 164 patients who were eligible for inclusion. In three patients, the trauma team did not succeed to obtain an extra tube of blood; the blood tube was incorrectly placed in the machine in two cases, and too little blood was drawn in the tubes in three cases. Thus, the trauma team was able to successfully start the point-of-care flow cytometry analysis in 156 of 164 patients (95%). A total of 57 of 156 patients (37%) did not give informed consent to use their clinical and/or flow cytometry data. This finally resulted in a total of 87 patients who were included for further analysis of neutrophil markers.

![Flowchart of patient inclusion.](cc9-2-e0158-g001){#F1}

Baseline Characteristics
------------------------

Of these 87 patients, 32 patients sustained severe injuries (Injury Severity Score \[ISS\] ≥ 16), and 55 patients had isolated injuries (ISS \< 16). During hospital admission, a third of the polytrauma patients (11/32; 34%) developed infectious complications. Baseline characteristics are shown in **Table [1](#T1){ref-type="table"}**. Only three of 55 monotrauma patients (5%) developed infectious complications. Polytrauma patients who developed infectious complications had a lower Glasgow Coma Scale (10 \[3--14\] vs 14 \[11--15\]; *p* = 0.009) and a lower systolic blood pressure (113 \[90--130\] vs 140 \[119--155\] mm Hg, *p* = 0.015) upon trauma bay presentation. This was associated with a significantly higher ISS (29 \[22--34\] vs 19 \[17--23\]; *p* = 0.002) and new ISS (41 \[27--48\] vs 22 \[22--27\]; *p* = 0.004). These patients also had a significantly longer ICU stay (9 \[7--21\] vs 1 d \[0--3 d\]; *p* \< 0.001) and total hospital stay (33 \[18--47\] vs 7 d \[3--11 d\]; *p* \< 0.001).

###### 

Comparison of Baseline Characteristics of Polytrauma Patients (Injury Severity Score ≥ 16) Who Developed Complications Compared With Polytrauma Patients Who Did Not Develop Complications
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Baseline Neutrophil Activation
------------------------------

Counterintuitively and in contrast with the current literature ([@R3], [@R11]), no signs of direct neutrophil activation were seen in either monotrauma patients or polytrauma patients, as measured by the panel of antibodies directed against activation markers. The baseline expression of these neutrophil activation markers of all included patients is shown in **Figure [2](#F2){ref-type="fig"}*A--F***. The activation markers CD35, CD11c, CD11b, CBRM1/5, CD10, and CD66b showed no significant differences between polytrauma patients who developed infectious complications during hospital admission and polytrauma patients who did not.

![Expression of neutrophil activation markers of all included polytrauma patients (Injury Severity Score \[ISS\] ≥ 16). Neutrophil markers CD35 (**A**), CD11c (**B**), CD11b (**C**), CD10 (**D**), CD66b (**E**), and active CD11b (CBRM1/5) (**F**) were measured without the bacterial stimulus fMLF. The effect of activation (N-formyl-methionyl-leucyl-phenylalanine \[fMLF\]+) on the expression of neutrophil activation markers CD35 (**G**), CD11c (**H**), CD11b (**I**), CD10 (**J**), CD66b (**K**), and active CD11b (CBRM1/5) (**L**) is shown. Polytrauma patients without infections (*n* = 21) (•) were compared with polytrauma patients with infections (*n* = 11) (▪) with the use of a Mann-Whitney *U* test. Data are presented as scatter plot with median and interquartile range. Reference values (*gray area*) show interquartile range of monotrauma patients (ISS \< 16) (*n* = 55). AU = arbitrary units, MFI = median fluorescent intensity.](cc9-2-e0158-g003){#F2}

Neutrophil Responsiveness
-------------------------

Neutrophil responsiveness that is determined by the expression of neutrophil activation markers in the presence of the bacterial stimulus fMLF is shown in **Figure [2](#F2){ref-type="fig"}*G*--*L***. Significantly lower responsiveness of neutrophils for the activation-specific epitope of CD11b (CBRM1/5) was found in the infection group compared with the no infection group (*p* = 0.034). No significant difference in responsiveness was found for the other neutrophil markers CD35, CD11c, CD11b, CD10, and CD66b although trends toward less neutrophil responsiveness were visible for some markers.

Neutrophil Phenotypes
---------------------

After trauma, two neutrophil phenotypes were found in the peripheral blood that is characteristic for systemic acute inflammation: CD16^dim^/CD62L^bright^ neutrophils and CD16^bright^/CD62L^dim^ neutrophils ([@R16]). Representative examples of differences in the percentage of these neutrophil phenotypes under different conditions (healthy controls, monotrauma patients, polytrauma patients and very severely injured polytrauma patients) are shown in **Figure [3](#F3){ref-type="fig"}**. Monotrauma patients show up to 6% CD16^dim^/CD62L^bright^ neutrophils, and polytrauma patients show up to 22% CD16^dim^/CD62L^bright^ neutrophils. In very severe polytrauma patients, mature neutrophils seem to have partially disappeared from the circulation, and many progenitor cells are left. This phenotype is in this cohort associated with a 100% mortality rate.

![Representative examples of differences in neutrophil phenotypes in patients with different injury severity. Healthy controls (**A**) and trauma patients without any injuries (**B**) show very little CD16^dim^/CD62L^bright^ neutrophils. Monotrauma patients (Injury Severity Score \[ISS\] \< 16) show up to 6% CD16^dim^/CD62L^bright^ neutrophils (**C**) and polytrauma patients (ISS ≥ 16) show up to 22% CD16^dim^/CD62L^bright^ neutrophils (**D**). In very severe polytrauma patients, mature neutrophils seem to have partially disappeared from the circulation and many progenitor cells are left. This phenotype is associated with a 100% mortality rate (**E**). PMN = polymorphonuclear leukocytes.](cc9-2-e0158-g004){#F3}

Next, it was evaluated whether an association was present between the presence of neutrophil phenotypes and infectious complications. The percentage CD16^dim^/CD62L^bright^ and CD16^bright^/CD62L^dim^ neutrophils in mono- and polytrauma patients was plotted in **Figure [4](#F4){ref-type="fig"}**. Monotrauma patients were characterized by the presence of 0.5% (0.3--1.5%) CD16^dim^/CD62L^bright^ neutrophils and 1.2% (0.6--3.2%) CD16^bright^/CD62L^dim^ cells. Polytrauma patients who developed infectious complications had a significantly higher percentage CD16^dim^/CD62L^bright^ neutrophils than polytrauma patients without infections (8.4% \[6.7--11.8%\] vs 3.1% \[1.3--6.8%\]; *p* = 0.002) despite no significant difference in percentage CD16^bright^/CD62L^dim^ neutrophils (6.9% \[3.6--12.7%\] vs 3.6% \[1.0--9.4%\]; *p* = 0.090). Area under the curve value with 95% clearance interval for %CD16^dim^/CD62L^bright^ neutrophils is 0.90 (0.83--0.97) (**online supplement fig. 2**, Supplemental Digital Content 2, <http://links.lww.com/CCX/A225>).

![Percentage of CD16^dim^/CD62L^bright^ neutrophils (**A**) and CD16 ^bright^/CD62L^dim^ neutrophils (**B**) in polytrauma patients without infections (*n* = 21) (•) and with infections (*n* = 11) (▪). Data are presented as a scatter plot with median and interquartile range and analyzed with the use of a Mann-Whitney *U* test. Reference values (*gray area*) show interquartile range of monotrauma patients (Injury Severity Score \[ISS\] \< 16) (*n* = 55). ^\*\*\*^*p* \< 0.005.](cc9-2-e0158-g005){#F4}

DISCUSSION
==========

Feasibility of Flow Analysis of Innate Immune Cells by a Point-of-Care Automated Flow Cytometer in the Trauma Bay
-----------------------------------------------------------------------------------------------------------------

This study demonstrates the feasibility of a fully automated flow cytometer used point-of-care in the emergency bay to analyze the state of the innate immune response in trauma patients presented without the help of experienced laboratory personnel. The trauma team on-duty was able to include 156 of 164 patients eligible for inclusion during the 2.5-month inclusion period resulting in a success rate of 95%.

With the introduction of the fully automated flow cytometer in the trauma bay, several steps had to be taken to ensure an optimal workflow: 1) Correct placement of the automated flow cytometer is essential. The machine needs to be placed in a point-of-care setting or in any place where the time from blood drawing until analysis will be maximum 30 minutes because minimal time delay is essential for quick and reliable measurements of neutrophil markers ([@R13]) and 2) The machine needs to be 24/7 available to start immune analysis in trauma patients. The AQUIOS CL is made for 24/7 measurements provided that reagents are checked and quality control is implemented.

Handling Failure
----------------

All the aforementioned steps were taken care of before the start of this study, which resulted in a high success percentage of 95%. However, there were several learning points for further implementation. In three cases, too little blood was drawn because blood was not visible in the tube due to incorrect placement of the barcode. In two additional cases, the blood tube with the barcode was placed incorrectly in the tray precluding the adequate reading of the barcode and the start of the machine. These issues were resolved by using multiple barcode stickers.

Informed Consent Procedure
--------------------------

For this study, written informed consent was required to collect clinical data and flow cytometry results of the included trauma patients. Informed consent procedures in emergency medicine are a challenge for testing fast procedures, particularly when proxy consent is needed that is often the case with severely injured patients ([@R17]). Therefore, our institutional ethical review board approved delayed consent. Despite the fact that delayed informed consent could be obtained, still 37% of the patients did not give written informed consent to participate in this study. The most important reason for this was that a significant part of the patients was sent home after the initial medical examination or soon after admission. The low response rate after hospital discharge is a known problem in the trauma population ([@R18]--[@R20]). The informed consent procedure caused a selection bias in this study, as it led to the exclusion of less severely injured trauma patients who were rapidly discharged from the hospital. To minimize selection bias, this analysis was only performed with the cell markers obtained from the polytrauma patients. In this subgroup, a total of 87% did give informed consent.

Biomarkers Associated With Injury Severity and Infectious Complications
-----------------------------------------------------------------------

Up to now, no clear biomarker has been identified that adequately correlates with the severity of tissue damage and the following immune response directly after trauma. The ISS and new ISS are widely used scoring methods for trauma patients who show a correlation with clinical outcomes but are obtained after final evaluation ([@R21], [@R22]). Hence, it is not a useful tool for the initial evaluation of the clinical (immune) status of trauma patients. Base excess at admission has a clear correlation with injury severity and mortality after trauma, as it is indicative of inadequate perfusion and tissue hypoxia ([@R23]--[@R25]). However, there are a number of comorbidities that can change acid-base deficit as well, for example, diabetic ketoacidosis, substance intoxication, or a prevalent condition as kidney insufficiency ([@R25]).

Several studies have tried to find early markers with predictive value for posttraumatic infectious complications. Biomarkers that seemed useful included the expression of human leukocyte antigen--DR isotype on circulating monocytes and procalcitonin levels in the peripheral blood ([@R26]--[@R28]). The best predictive value for septic complications was found for procalcitonin at day 1 post trauma, with only a reasonable sensitivity and specificity of up to 70% in a multivariate model ([@R26]).

Literature shows a huge cytokine storm 4--12 hours after trauma ([@R3]). Pro- and antiinflammatory cytokines are released in this timeframe ([@R3]). However, measuring only proinflammatory cytokines as interleukin-8, C5a, and leukotrienes such as Leukotriene B4 would not show the real status of the innate immune system as the antagonizing antiinflammatory markers will affect overall status of the system. Measuring neutrophil receptor expression, as an integrator of all pro- and antiinflammatory cytokines, is a better indicator of the status of the innate immune response. Recently, neutrophil marker analysis showed a better prognostic value in the prediction of septic shock, with a sensitivity of up to 90% ([@R3], [@R8], [@R11]). Therefore in this study, baseline neutrophil activation, neutrophil responsiveness to fMLF, and analysis of neutrophil phenotypes were used to find potentially a better clinical applicable biomarker that would be correlated with injury severity and the resulting immune response.

Baseline Neutrophil Activation
------------------------------

With the introduction of an automated flow cytometer in a point-of-care setting, a more accurate measurement method of neutrophil activation markers was applied ([@R13]). Surprisingly, applying this improved method, no significant differences were found between the expression of activation markers on neutrophils of monotrauma patients and polytrauma patients. In marked contrast, several studies in the literature showed a significant up-regulation of neutrophil activation markers after trauma (e.g. CD11b) ([@R3], [@R11], [@R29], [@R30]). However, marked variances in marker expression were demonstrated, and no clear correlation was found with tissue damage nor infectious complications. Some studies found a higher expression of CD11b, whereas some studies found a lower expression of CD11b in polytrauma patients compared with monotrauma patients ([@R2], [@R3]). A putative explanation for this discrepancy is that the increase in neutrophil activation markers shown in previous studies was at least in part a result of ex vivo manipulation ([@R13]).

Neutrophil Responsiveness
-------------------------

Automated flow cytometry analysis of neutrophil responsiveness to the bacterial stimulus fMLF was also performed in every trauma patient. Several studies showed that neutrophil responsiveness provides useful information ([@R2], [@R8], [@R11]--[@R13], [@R31]). In line with the literature, we found lower neutrophil responsiveness in polytrauma patients with infectious complications compared with polytrauma patients without infectious complications. However, this was only significantly found for the fMLF-induced expression of the neoepitope of CD11b (CBRM1/5) that recognizes only an active configuration of this integrin ([@R32]).

Neutrophil Phenotypes
---------------------

Literature showed a significant increase in CD16^bright^/CD62L^dim^ neutrophils in trauma patient samples collected within 1 hour after trauma, as well as 4--12 and 48--72 hours post injury ([@R3]). Up to now, no detailed kinetics on the appearance of CD16^dim^/CD62L^bright^ neutrophils after trauma has been published. The CD16^dim^/CD62L^bright^ neutrophils usually characterized by a banded shaped nucleus are most likely released from the bone marrow ([@R16], [@R33]). It is tempting to speculate that the amount of tissue damage leading to the liberation of damage-associated molecular patterns and production of immune mediators correlated with the release of new neutrophils from the bone marrow. This hypothesis is corroborated with the correlation that was found between CD16^dim^/CD62L^bright^ neutrophils and the ISS. However, there is only a limited correlation between the ISS and the amount of tissue damage ([@R34]). Therefore, it seems plausible that the bone marrow response leading to mobilization of CD16^dim^/CD62L^bright^ neutrophils might be a better measure for the cumulative amount of tissue damage.

We found a significant relation between CD16^dim^/CD62L^bright^ neutrophils and infectious complications in polytrauma patients. This can be used for the prediction of infectious complications in trauma patients, as supported by the high predictive values found in this study (online supplement fig. 2, Supplemental Digital Content 2, <http://links.lww.com/CCX/A225>). Furthermore, the %CD16^dim^/CD62L^bright^ neutrophils was a significant covariate, when tested in a binary logistic regression model. However, the number of patients was too low to analyze the predictive value of CD16^dim^/CD62L^bright^ neutrophils in a multivariate analysis that includes other factors as well.

CONCLUSIONS
===========

This study showed the feasibility of the implementation of a fully automated point-of-care flow cytometry system for the characterization of the cellular innate immune response in trauma patients. This study supports the concept that assessment of CD16^dim^/CD62L^bright^ neutrophils can be used for early detection of patients at risk for infectious complications. Furthermore, this can be used as a first step toward immuno-based precision medicine of polytrauma patients at the ICU.
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